In 2006, Craig Mello, Ph.D., and Andrew Fire, Ph.D., received the Nobel Prize for Medicine for the discovery of RNA Interference (RNAi). Alnylam is recognizing the 10th anniversary of this historic achievement and the progress made toward delivering RNAi therapeutics, an entirely new class of innovative medicines to patients. Explore this page to learn more about our story and the scientific journey of RNAi—from possibility, to potential treatment for patients.

This microsite is best viewed on Google Chrome or Safari. There may be compatibility issues with Internet Explorer.

The Eureka Moment

In truly groundbreaking research, there is often a moment of clarity, a moment when you realize that your discovery has the potential to transform science and medicine as we know it.  This is the Eureka moment on which Alnylam was built.  Click on image to play video.

Top

What's in a Name?

Our name may not be the easiest to pronounce – but once you learn it, you never forget it.  “Alnilam” is the Arabic word for “string of pearls” and is also the center star in Orion’s belt, shining the brightest of them all. Both are fitting with our mission to build a top-tier biopharmaceutical company and to make the future brighter for patients.  Click on image to play video.

Top

The Scientific Odyssey

The RNAi Boom

There was a time when interest in RNAi boomed. Everyone wanted a piece of it.  Excitement for this promising new approach to treating disease drew in multiple pharmaceutical players, millions of dollars, and ambition to be the first to unlock the power of this new discovery. Click on image to play video.

 

 

The Dark Ages

Alnylam faced many challenges in its early history. The dissolution of major partnerships led to turmoil and a loss of faith in the technology outside the walls of Alnylam.  Within the company there remained an unwavering belief, a continued focus, and enthusiasm and drive to make RNAi therapeutics a reality. Click on image to play video.

 

 

The Slope of Enlightenment

After overcoming seemingly insurmountable hurdles, Alnylam has built an R&D engine and product pipeline with the potential to address a broad spectrum of diseases. Today, Alnylam is dedicated to proving that innovative science, perseverance, and passion can come together to improve the lives of patients. Click on image to play video.

 

 

Top

Exploring New Frontiers

As a leader in the development of RNAi therapeutics, Alnylam is focused on three Strategic Therapeutic Areas (STArs).  These include: genetic medicines, cardio-metabolic diseases and hepatic infectious diseases, spanning from the rare, to the common, to global. 

 

From Possibility to Patients

From science to medicine, from bench to bedside, from possibility to patient, Alnylam has advanced RNAi from a groundbreaking raw science to a robust pipeline of innovative investigational therapies. Click on image to play video.

Top

Exploring New Frontiers

As a leader in the development of RNAi therapeutics, Alnylam is focused on three Strategic Therapeutic Areas (STArs).  These include: genetic medicines, cardio-metabolic diseases and hepatic infectious diseases, spanning from the rare, to the common, to global.

 

Return to Alnylam.com